Anifrolumab Treatment Improves Patient-Reported Quality of Life and Decreases Disease Activity and Corticosteroid Use in Patients with Systemic Lupus Erythematosus: A Qualitative Study in Denmark

The study in Denmark on Anifrolumab treatment for systemic lupus erythematosus (SLE) involved 16 patients and demonstrated significant improvements in patient-reported quality of life, reduced disease activity, and decreased corticosteroid use. Patients experienced a reduction in symptoms such as fatigue, joint pain, and hair loss, with disease activity scores dropping from an average of 9 to 2 over six months. The treatment allowed 44% of patients to avoid reintroducing steroids during flares. Despite the small sample size, the study underscores the positive impact of Anifrolumab on both subjective experiences and clinical outcomes in SLE management.